[caption id="attachment_98850" align="alignnone" width="830"] © 2025 European Academy of Neurology[/caption] The 11th Congress of the European Academy of Neurology (EAN) delivered ground-breaking insights across neurology, showcasing how precision medicine is reshaping clinical practice. Taken from the EAN Highlights and ...
Prof. Simona Sacco outlines the European Stroke Organisation’s (ESO) strategic priorities to reduce disparities in stroke care across Europe. She discusses the transformative impact of the ESO East programme and the Stroke Action Plan for Europe (SAP-E), and also reflects on the increasing role of artificial intelligence (AI) in stroke diagnostics and treatment pathways.
Watch leading experts discuss evolving fluid biomarkers for AD and assess current blood biomarkers for diagnosing AD in the clinic.
Prof. Michael Schöll joins us at EAN 2025, to discuss how plasma biomarkers are reshaping Alzheimer’s diagnostics, though not yet in routine clinical use. He explains the growing role of biomarkers like p-tau217 in MCI pathways, the challenges clinicians face without clear guidelines, and why blood-based and digital biomarkers, alongside new therapies, are the future of dementia care.
Watch experts discuss strategies to accelerate MG diagnosis and treatment, plus consider emerging therapies.
At EAN 2025, Prof. K. Ray Chaudhuri shares insights into cutting-edge Parkinson's drug delivery methods, the future of biomarker-driven care, advances in managing sleep disturbances, and the vital role of lifestyle modifications in optimizing patient outcomes.
Prof. Bengt Winblad shares insights EAN 2025 on the evolving landscape of Alzheimer’s diagnosis and treatment. He discusses the growing role of biomarkers, the balance between early detection and clinical accuracy, and the challenges posed by the COVID-19 pandemic on dementia care. Prof. Winblad also explores emerging therapies, including monoclonal antibodies, and highlights the importance of combining biomarkers with cognitive testing to improve diagnostic precision and address the rise in undiagnosed cases post-pandemic.
At EAN 2025, Prof. Moccia shared his perspective on the evolving multiple sclerosis McDonald criteria, the role of advanced imaging and fluid biomarkers, and the exciting innovations reshaping MS diagnosis and management.
In this episode of Visionary Voices, Dr Anthony Caggiano, Chief Medical Officer at Cognition Therapeutics, joins us to explore how biomarkers are transforming our understanding of Alzheimer’s disease, from diagnosis and disease progression to drug development and the future of clinical care.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper and lower motor neurons that results in progressive motor impairment. ALS is the most common disease of motor neurons with an annual incidence of approximately 1.7–2.5 per 100,000 people. It is a ...
Multiple sclerosis (MS) is a chronic neurological condition that often presents with vague or intermittent symptoms, making early recognition particularly challenging in primary care. As diagnostic delays can significantly impact long-term outcomes, timely identification and referral are critical. In alignment ...
In this Q&A, Dr Andy Liu, Associate Professor of Neurology at Duke University School of Medicine, discusses his presentation on the clinical use of lecanemab in Alzheimer’s disease. Drawing on real-world experience and findings from the 2022 CLARITY AD study, Dr Liu explores the treatment’s benefits, challenges in daily practice and the importance of patient-centred care in this evolving therapeutic landscape.
Watch a leading expert discuss the key signs and symptoms of Friedreich ataxia and how to avoid diagnostic delays.
Amyotrophic lateral sclerosis (ALS) is characterized by the degeneration of both upper and lower motor neurons, which ultimately leads to muscle weakness, atrophy, spasticity and contractures.1 ALS typically manifests in the 50–60 years age range, although familial cases may present in ...
touchNEUROLOGY is delighted to congratulate Dr Amit Bar-Or of Penn Medicine on receiving the 2025 John Dystel Prize for Multiple Sclerosis Research, jointly awarded by the National Multiple Sclerosis Society (NMMS) and the American Academy of Neurology (AAN). This honour recognizes his groundbreaking work in neuroimmunology, precision medicine, and biomarker research in multiple sclerosis (MS).
Over the past two decades, the understanding and management of multiple sclerosis (MS) have advanced dramatically, reshaping long-held views of the disease. MS is now increasingly seen as a continuous spectrum rather than a condition with distinct phases, with evidence showing it can begin silently, even before clinical symptoms emerge. Technological and diagnostic innovations have enabled the detection of early brain changes and biomarkers, opening doors to earlier diagnosis and intervention. New diagnostic criteria allow MS to be identified without a clinical event, and studies on disease-modifying therapies (DMTs) support the benefits of early treatment. A major shift in treatment strategy is also underway, emphasizing early, aggressive approaches and therapies that target progression rather than just relapses, which are no longer seen as the main driver of long-term disability. A pivotal development in MS research is the confirmation of Epstein–Barr virus (EBV) as a fundamental trigger of the disease, with new evidence pointing to specific viral protein regions as higher-risk factors. Despite these strides, MS research remains a dynamic and evolving field, with much still to be uncovered beneath the surface.
New 48-week data from the ongoing Phase 3 KINECT 4 study evaluating valbenazine for the treatment of tardive dyskinesia (TD) have been presented at the 2025 Psychiatry Update Conference in Chicago. The finding showed the majority of participants reached a defined threshold for remission of TD regardless of underlying psychiatric disorder.
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.